If anyone thought the controversy over the primary mode of action (PMOA) in combination products was resolved, the response to the FDA draft product jurisdiction rule shattered that belief. Two stakeholders, including the Advanced Medical Technology Association, said the draft fails to incorporate legislative requirements that the agency not use any chemical action as an excuse to determine the product is a drug, and thus revives the risk that a combo product will be misclassified.